Abstract

BackgroundThis study explores young people’s daily experiences of living with Juvenile Idiopathic Arthritis (JIA) and their thoughts, beliefs and feelings related to the biological drug Etanercept, prescribed as part of their treatment.MethodsAn Interpretive Phenomenological approach was used to allow in-depth examinations of the young people’s personal accounts of their lived experiences. Data were obtained from 6 young people between the ages of 10–13 years, from one tertiary institution’s Paediatric Rheumatology department using audio-taped open-ended interviews.ResultsThe transcripts yielded seven thousand words of data and two hundred significant statements, which were reduced to five themes; 1) Who understands me, 2) Medicines and injections, 3) Challenges of schooling and friendships, 4) Being different, and 5) Exclusion from sports. There were marked similarities between the young people’s statements; however, there were also some striking differences. The theme ‘Who understands me’ yielded the biggest section of data, but also produced the biggest disparity between the young people. Two patients were very clear that they thought everyone ‘understands’, whilst two other patients held the belief that ‘no one understood’. This paper explores these statements in further detail.ConclusionsThe findings from this study can give healthcare professionals novel insight into the likely reactions to-treatment for JIA and, through this, enable them to offer improved support, education and early intervention before these issues become a concern. This study also provides insight into the emotional resilience of young people with JIA.Electronic supplementary materialThe online version of this article (doi:10.1186/s12969-016-0083-7) contains supplementary material, which is available to authorized users.

Highlights

  • This study explores young people’s daily experiences of living with Juvenile Idiopathic Arthritis (JIA) and their thoughts, beliefs and feelings related to the biological drug Etanercept, prescribed as part of their treatment

  • This study aimed to be inclusive, capturing young people’s views on their arthritis and biological medication, so the view of these individuals was felt to be just as valid as others, we acknowledge that prior experience in those with sytemic JIA may be different from those with Polyarticular JIA at onset

  • At the time of interview, the number of current active joints ranged from 1–9 in all the young people, none were in remission

Read more

Summary

Introduction

This study explores young people’s daily experiences of living with Juvenile Idiopathic Arthritis (JIA) and their thoughts, beliefs and feelings related to the biological drug Etanercept, prescribed as part of their treatment. Etanercept, a tumour necrosis factor (TNF)-alpha receptor antagonist (anti-TNF), was the first biological agent approved for use in JIA, and is given either. The biological efficacy of Etanercept is established, how children and young people feel when receiving the therapy is unexplored. Some research has been conducted to explore the psychological responses to success or failure of drug treatment in adult patients, but few studies so far have focussed on young people receiving biologic therapies and how they assess its impact. The aim of this study was to understand the Livermore et al Pediatric Rheumatology (2016) 14:21 young people’s perspectives of living with JIA receiving therapy with biologic agents

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call